By Application
Hot products 
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Rat Anti-(1-5)-α-L-Arabinan Recombinant Antibody (V2-501861) (CBMAB-XB0003-YC)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Mouse Anti-ABL2 Recombinant Antibody (V2-179121) (CBMAB-A0364-YC)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-CTCF Recombinant Antibody (CBFYC-2371) (CBMAB-C2443-FY)
-
Mouse Anti-ACKR3 Recombinant Antibody (V2-261265) (CBMAB-C1023-LY)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Mouse Anti-Acetyl SMC3 (K105/K106) Recombinant Antibody (V2-634053) (CBMAB-AP052LY)
-
Mouse Anti-AMH Recombinant Antibody (5/6) (CBMAB-A2527-YC)
-
Mouse Anti-DISP2 Monoclonal Antibody (F66A4B1) (CBMAB-1112CQ)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Mouse Anti-FOXL1 Recombinant Antibody (CBXF-0845) (CBMAB-F0462-CQ)
-
Mouse Anti-EGR1 Recombinant Antibody (CBWJZ-100) (CBMAB-Z0289-WJ)
-
Mouse Anti-ARSA Recombinant Antibody (CBYC-A799) (CBMAB-A3679-YC)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
-
Rat Anti-EMCN Recombinant Antibody (28) (CBMAB-E0280-FY)
-
Mouse Anti-BZLF1 Recombinant Antibody (BZ.1) (CBMAB-AP705LY)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
Carcinoid
Fig.1 Carcinoid
Carcinoid (also carcinoid tumor) is a slow-growing type of neuroendocrine tumor developing from the cells of the neuroendocrine system. The tumors of the midgut (jejunum, ileum, cecum and appendix) are related to carcinoid syndrome. Carcinoid tumors overwhelmingly show as malignant tumor of the appendix, but they are most commonly related to the small intestine, and they can also be found in the stomach and rectum. They are considered to grow in the liver, but this finding is normally a display of metastatic disease from a primary carcinoid occurring somewhere in the body. They have a very mind growth rate compared to most malignant tumors. The median age at diagnosis for all patients with neuroendocrine tumors is 63 years. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with MRI or CT, labs for tumor markers such as serotonin can be applied.
Loading...
Compare
